Theserotoninsyndromeanditstreatment
P.K.Gillman
ConsultantPsychiatrist(PrivatePractice),POBox8183,MountPleasant,Queens land4740,Australia.
Serotonin syndromeiscausedbydruginducedexcessofintrasynapti c5-hydroxytryptamine .Theclinical
manifestationsaremediatedbytheactionof5-hydroxytryptamine onvarioussubtypesofserotonin receptors.
Thereisnoe¡ectivedrugtreatmentestablished.Thehistory ofthetreatmentofserotonin syndromewith5-
hydroxytryptamine blocking drugsisreviewed.Aliterature searchwasundertakenusing bothMedline anda
manualsearchoftheolderliterature.Report sofcasestreatedwith the5-HT 2blockerscyproheptadine and
chlorproma zine wereidenti¢edandanalysed.Thereissome evidencesuggesting thee¤cacyof
chlorproma zineandcyproheptadine inthetreatmentofserotoninsyndrome.Theevidenceforcyproheptadine
islesssubstantial,perhaps becausethedoseofcyproheptadine necessarytoensureblockadeofbrain 5-HT 2
receptorsis20^30mg,whichishigherthanthatusedinthecases reportedtodate(4^16mg).
Keywords:chlorprom azine;cyproh eptadine;seroton inantagonists;serot oninsyndrome;treatment
‘What experience and history teach isthis—that people and
government snever have learned anything from history, oracted on
theprinciple sdeduced from it’(Georg Wilhelm Hegel)
Introduction
Serotonin syndrome (SS) iscaused bydrug induced excess
ofintrasynaptic 5-hydroxytryptamine (5-HT). The clinical
manifestations aremediated bytheaction of5-HT on
various subtypes ofserotonin receptors. Cases ofprobable
SSfound intheliterature that were treated with the5-HT
receptor blockers chlorpromazine orcyproheptadine are
reviewed. Ofallthecases ofSSidentiﬁed, only these were
treated with chlorpromazine orcyproheptadine. The
response totreatment isestimated from thelimited data
available inthese reports.
There have been about 23deaths from SSreported inthe
medical literature inthelast10years, notincluding those
associatedwith3,4-methylenedioxymethamphetamine(MDMA)
toxicity (Tackley andTregaskis, 1987; Brennan etal.,1988;
Kline etal.,1989; Stern etal.,1992; Beasley etal.,1993;
Neuvonen etal.,1993; Nimmo etal.,1993; Braitberg, 1994;
Keltner, 1994; Hernandez etal.,1995; Power etal.,1995) and
itislikely that other deaths have occurred about which no
account hasbeen published. None ofthedeaths reported inthe
literature occurred during thetreatment ofdepressive illness
with irreversible monoamine oxidase inhibitors (MAOIs)
combined with tricyclic antidepressants (TCAs), i.e.mixed or
combined antidepressant treatment. This isprobably because
theTCAs that exhibit greater serotonin reuptake inhibitor
activity, intherapeutic dosages, have rarely been used
therapeutically with MAOIs. The most potent serotonin
reuptake inhibitors oftheTCAs areclomipramine (CMI)
andimipramine (IMI) (Richelson, 1984) andwhen they havebeen combined with MAOIs, inoverdose oraccidentally, they
have often caused SS.
Background
There were reports ofSSfrom animal research starting in1958
(Bogdanski etal.,1958; Horita andGogerty, 1958; Hess etal.,
1959; Hess andDoepfner, 1961; Himwich andPetersen, 1961;
Himwich, 1962; Curzon etal.,1963; Nymark and Moller
Neilsen, 1963; Loveless and Maxwell, 1965; Rogers and
Thornton, 1969; Penn and Rodgers, 1971; Fahim etal.,
1972; Sinclair, 1973; Green andGrahame-Smith, 1976; Jounela
etal.,1977; Felner and Waldmeier, 1979; Fjalland, 1979;
Marsden andCurzon, 1979) andthese continued toaccrue
until theseminal papers ofMarley (Marley andWozniak,
1983; Marley andWozniak, 1984a,b; Marley andWozniak,
1985), usually without percolating through tothecorpus of
psychiatric literature. These early studies indicated thatsome
neuroleptics lessen symptoms ofSSinanimals (Bogdanski et
al.,1958; Himwich andPetersen, 1961; Sinclair, 1973; Green
andGrahame-Smith, 1974; Marley andWozniak, 1984b) and
that thehyperactivity syndrome which wasseen when some
analgesics were given incombination with MAOIs wasrelated
toexcess intra-synaptic 5-HT. Subsequent work hasshown
that meperidine anddextromethorphan have, inaddition to
their other properties, serotonin reuptake inhibitor activity
(Carlsson etal.,1969; Carlsson andLindqvist, 1969; Sinclair,
1973). Many MAOI/analgesic reactions have been recorded in
humans andthese have occurred onlywithanalgesics thathave
serotonin reuptake inhibitor activity (Mitchell, 1955; Papp and
Benaim, 1958; Palmer, 1960; Shee, 1960; Cocks andPassmore-
Rowe, 1962; Denton etal.,1962; London andMilne, 1962;
Taylor, 1962; Vigran, 1964; Pollock andWatson, 1971; Sovner
andWolfe, 1988; Hansen etal.,1990; Zornberg etal.,1991;Journal ofPsych opharmacolog y13(1) (1999) 100–109
&1999 BritishAssoci ation forPsych opharmacolog y(ISSN 0269-8811)
SAGE Publi cations, Londo n,Thousand Oaks, CAandNew Delhi
0269-8811 [199903] 13:1; 100–109; 005989P.K.GILLMAN:THESEROTONINSYNDROME 101
Zornberg, 1993; Jahr etal.,1994; Mason and Blackburn,
1997). Even moclobemide (MOC), aselective reversible
inhibitor ofMAO-A (RIMA) with avery short half-life, has
been implicated inproducing SSintherapeutic dosages, both
with relatively weaker serotonin reuptake inhibitors such as
IMI (Brodribb etal.,1994), meperidine (Gillman, 1995),
ﬂuoxetine (Benazzi, 1996; Liebenberg andBerk, 1996), and
more potent serotonin reuptake inhibitors such asparoxetine
(Robert etal.,1996). Itislikely thattheriskofSSwithMOC is
much lower than with MAOIs.
Thepresentstate
There isnoestablished deﬁnition ofthediagnostic features of
SS;indeed, itisnotadiscrete entity with diagnostic features
(Hilton etal.,1997; Lane andBaldwin, 1997). Calling ita
syndrome may bemisleading inthesense that itisa
manifestation ofincreasing intra-synaptic 5-HT levels to
which everyone isliable, notanidiosyncratic response like
neuroleptic malignant syndrome (NMS). Itmay bemore
relevant and helpful toascertain thesymptoms and signs
associated with increasing degrees ofseverity.
The picture inhumans iscongruent with that seen in
animals given drugs that increase intra-synaptic 5-HT. This
ischaracterized byenhanced locomotor activity, forepaw
treading, shivering, tremors, hyperexcitability, dilated pupils,
salivation, ﬂushing, tachypnoea, hypertension, lateral head
weaving, hind limb abduction, arched (straub) tail,pyrexia,
myoclonus and seizures (Bogdanski etal.,1958; Himwich
and Petersen, 1961; Sinclair, 1973; Marley and Wozniak,
1983). There ismuch imprecision indeﬁnitions ofSS;the
term ‘mental status changes’ hasbeen used without precise
deﬁnition. Some features arelikely torepresent different
points onacontinuum ofseverity, e.g. poor concentra-
tion4memory impairment 4confusion 4delirium, orvarious
forms ofthe same basic phenomenon, e.g. clonus,
myoclonus, ocular oscillations, ‘oculo-gyric crisis’ andeyes
deviated upward. One primary element isthehyperactivity
which manifests inmental (agitation, hypomania) and
physical (restlessness and hyperactivity) forms. The other
key features are hyperreﬂexia, hypertonia/rigidity and
particularly clonus (inducible, spontaneous and ocular)
(Sternbach, 1991; Hilton etal.,1997). The keyfeatures of
SSandNMS arecontrasted inTable 1.
Until the1980s, itwas notgenerally understood that
symptoms were related toexcessive intra-synaptic concentra-
tions of5-HT. This hypothesis had, however, been advanced
byaneurologist, Oates, in1960 following observations of
symptoms inpatients treated withanMAOI andL-tryptophan
(Oates andSjoerdsma, 1960).
The literature about SSisexpanding rapidly; recent
reviews summarize theﬁeld (Bodner etal.,1995; Lejoyeux
etal.,1995; Mills, 1995; Sporer, 1995; Brown etal.,1996;
Martin, 1996; Brubacher, 1997; Hilton etal.,1997; Lane and
Baldwin, 1997). However, fewreviews have concentrated on
treatment andsome ofthecases reported here have never
been analysed.Methods
Many episodes ofSSintheliterature, from thelate1950s until
theearly 1980s, were unrecognized orhave been forgotten. The
author identiﬁed reviews thatdealt with ‘combined treatment’
(TCAs andMAOIs) andstudied them foranyreports that
might represent SS(Ayd, 1961a; Bowen, 1964; Gander, 1965;
Schuckit etal.,1971; Beaumont, 1973; Sethna, 1974; Ananth
andLuchins, 1977; Moller Nielsen, 1980; White andSimpson,
1981; Razani etal.,1983; Lieberman etal.,1985; Clark and
Lipton, 1986; Goldberg and Thornton, 1986). One review
considers alldrugs which affect body temperature inanimals
andhumans andcontains 794references (Clark andLipton,
1986). Allthedrugs mentioned inthepresent article thathave
been implicated inSSwere cross-checked forhuman cases
which were then checked toseeiftheymettheclinical criteria
forSS.Anextensive manual search oftheliterature before the
start oftheMedline database revealed numerous reports in
humans. Atotal of12reports ofpossible SSwere identiﬁed
before theendof1962 (Mitchell, 1955; Papp andBenaim, 1958;
Palmer, 1960; Shee, 1960; Ayd, 1961b; Babiak, 1961; Brownlee
andWilliams, 1961; Harrer, 1961; Howarth, 1961; Clement and
Benazon, 1962; Cocks andPassmore-Rowe, 1962; Reid, 1962).
Computer searches using theterms ‘hyperthermia’, ‘hyperpyr-
exia’, ‘serotonin syndrome’, or‘toxic’ and ‘serotonin’ and
‘MDMA’ were carried outandtheresultant abstracts scanned.
Inaddition, reports ofNMS were examined toascertain
whether cases hadbeen misclassiﬁed. Thecriteria used inthisTable 1Serotonin syndrom e(SS) versus neuroleptic malignant
syndrome (NMS)
Feature SS NMS
Serotonin syndrom e
Serotomime ticdrug +++ 0
Rapid onset +++ 0
Mental state changes—ag itation +++ Akathisiaa
Mental state changes—c onfusion + ++
Mental state changes—h yperactivity +++ 0
Clonus +++ 0
Myoclonus +++ 0
Ocular oscillations +++ 0
Shivering +++ 0
Tremor +++ +
Hyperreﬂe xia +++ 0
Neuroleptic malignant syndrome
Neuroleptic 0 ++
Slow onset 0 ++
Bradykines ia/stupor 0 +++
Leaden rigidity 0 +++
Autonomic instability +b++
Non-speciﬁ c
Hyperpyrex ia ++ ++
Diaphoresis ++ +++
Tachypnoea ++ +++
Tachycard ia ++ +++
Hypertensio n ++ ++
Confusion ++ +++c
Raised creatinine phosphokin ase + +++
aAkathisia andagitation may behard todistinguish between.bAuto-
nomic instability, mayonlyoccur insevere cases.cConfusion, probabl y
more severe inNMS.102 JOURNALOFPSYCHOPHARMACOLOGY13(1)
present paper forassessing whether acasewasoneofprobable
SSareinaccord with thereports inTable 1.
Thedegree ofseriousness ofsymptoms (Table 2)hasbeen
classiﬁed asmild, moderate orsevere asanapproximate guide
forcomparison. Mild signiﬁes three deﬁnite symptoms from
Table 1butnorequirement foraction (e.g. treatment or
admission tohospital); moderate signiﬁes fourormore deﬁnite
symptoms from Table 1which between them cause signiﬁcant
impairment offunctioning ormake medical observation
necessary; severe signiﬁes thatmost symptoms from Table 1
arepresent orsigniﬁcant impairment ofconsciousness or
functioning ispresent, toanextent mandating hospital care
andactive treatment. Further research isrequired todeﬁne
more precisely thepattern andprogression ofsymptoms.
Results
Table 2summarizes thetreatment andestimated response of
cases given chlorpromazine andcyproheptadine. Inchlorpro-
mazine treated cases (atotal of13)seven episodes were severe
andofthese there wasagood response inthree andapoor
response infour. Thepoor response, Ciocatto’s case, followed
adose of10mgofchlorpromazine (Ciocatto etal.,1972). Four
episodes were rated asbeing ofmoderate severity andofthese
there wasagood response inthree andmoderate response in
one. Two cases were rated asmild; these arethepreviously
unreported cases from thepresent author. They occurred in
patients under close observation inaspecialist unitandwere
notunexpected. They were treated atanearly stage.
Inthecyproheptadine treated cases (atotal ofseven), none
were rated assevere andonly three asdeﬁnite SS.Only three
outoftheseven were ofmoderate severity and, ofthese, one
response wasgood, another wasmoderate andthethird was
poor. Allthree deﬁnite cases involved MAOIs, with one
response rated asgood, asecond asmoderate andthethird
(given ahigh dose ofcyproheptadine) asnoresponse atall.Of
thetotal ofseven cases, onedidnotfulﬁl criteria forSSand
oneshould beregarded asa‘possible’, leaving only ﬁveas
probable ordeﬁnite. Three ofthese ﬁveeither hadnoorapoor
response. Inonlyonecasewastheresponse rated asgood. The
improvement, within 30minofonly4mgofcyproheptadine, is
rapid fororalonset ofaction andmay represent spontaneous
resolution.
Discussion
There isgreat difﬁculty inassessing response insuch cases
where thenatural course ofthereaction isnotknown with
certainty. Thevaried nature andcircumstances ofthese reports
prevents much useful comparison with other cases nottreated
with chlorpromazine orcyproheptadine. Allthesevere cases
occurred with MAOIs. The deﬁnite cases treated with
cyproheptadine were ofmoderate severity and show little
indication ofimprovement, onlyonewasrated asamoderately
good response. Inthechlorpromazine cases, there isastronger
suggestion ofresponse; intheseven severe cases, three outofseven showed good response. Inthefour moderately severe
cases, three outoffour showed good responses andonea
moderate response. Itissalutary tonote from recent reports
how rapid (within 2h)patients’ deterioration canbe(George
andGodleski, 1996; Mathew etal.,1996; Robert etal.,1996),
especially with combinations such asCMI andtranylcypro-
mine (TCP) (Corkeron, 1995; Brubacher etal.,1996; Gillman,
1996). Both rapidity ofonset andseverity ofsymptoms are
related tohigh potency drugs, larger doses andtheroute of
administration (IV4IM4oral). Theduration ofthereaction
willhave some relationship totheelimination half-life which is
long with CMI andﬂuoxetine (Pato etal.,1991; Coplan and
Gorman, 1993). TheoldMAOIs bind irreversibly with MAO
which may take 2weeks ormore toreturn tonormal levels
(Arnett etal.,1987). SShasbeen reported upto4weeks after
ceasing aselective irreversible MAOI (clorgyline) (Insel etal.,
1982). Thelargest series offatal reactions documented (seven
deaths) waswith MAOIs given after ﬂuoxetine (Beasley etal.,
1993). Inthese cases, TCP wasstarted between 12h(case 1),
andafewdays, after ﬂuoxetine. These reports illustrate thata
thorough knowledge ofthepotency, pharmacodynamics and
pharmacokinetics ofdrugs isneeded tojudge thelikelihood of
reactions inindividual cases.
Small changes ofdosage ofsome drugs may markedly
increase effects andthere isevidence ofaﬁnelinebetween side-
effects andtoxicity; thiswasevident inseveral oftheauthor’s
cases, especially those involving TCP. Symptoms only devel-
oped after thedose hadbeen increased from 20–30 mgperday.
This accords with theauthor’s clinical impression from
treating many patients with TCP which isthat fewgetan
optimal improvement with lessthan 30mgperday. One
unusual paper reports theside-effects encountered in45cases
where CMI andTCP were administered together (Oefele etal.,
1986). Treatment was ceased because a‘toxic delirium’
occurred inthree cases, ‘instable (sic)blood pressure, sweating
andtremor’ infour other cases andinafurther three ‘gross
tremor andhyperthermia’. Although the22% incidence of
severe side-effects mandating cessation oftreatment ishigh, it
isnoteworthy thatthere wasnomortality inthisseries. This
maybeattributable tothelowmaximum dose ofonly20mgof
TCP.
Serotoninsyndromeandneuroleptic
malignan tsyndrome:di¡erentialdiagnosis
Thedifferential diagnosis between SSandNMS (seeTable 1)
hascaused difﬁculties inafewreported cases (Brennan etal.,
1988; Kline etal.,1989; Staufenberg andTantum, 1989; Stern
etal.,1992; Ames andWirshing, 1993; Graber etal.,1994).
These difﬁculties have arisen partly because some patients were
taking neuroleptics, which seems tohave inﬂuenced the
exclusion ofadiagnosis ofSS.Apresumptive diagnosis of
NMS wasthusmade when theclinical picture indicated SS.In
onepatient (already onregular chlorpromazine), thedose of
chlorpromazine had just been reduced before symptoms
developed anditispossible that theprotective effect of5-
HTreceptor blockade, thus lessened, allowed symptoms to
emerge (Staufenberg andTantum, 1989).P.K.GILLMAN:THESEROTONINSYNDROME 103Table 2Drug treatm entofserotonin syndrom e
AuthorSeroto-
mimetic
drugsRapid
onset Shiveri ng TremorHyper-
active/agitated Confusion Clonus MyoclonusOcular
oscillati onsHyper-
reﬂexiaDiaphor-
esisHyper-
pyrexia Diarrhoea AtaxiaSS
diagnos isSympt om
severityDose
ofCPZ Comment sResponse
Papp iproni azid
150mg
dailyand
meperidine
200mg
IMI+++ +++ +++ +++ +++ Deﬁnite Severe 50mgIM Responde d
in30minGood
Clement iproni azid
andmeper-
idine 20mg
IV+++ +++ ++ +++ +++
(408C)Probabl eSevere 50mgIV Responde d
in20minGood
Grantham IMI
100mg
daily,
ceased,
nextday
TCP30mgAfter 6
days on
TCP++ ++ +++ +++ +++ ++
(39.48C)Deﬁnite Severe 50mgIM Severely ill
for24h.
Improve-
ment 1h
after CPZGood
Ciacotto ODofIMI
andTCP
(unkno wn
quantity)+ +++ +++ +++ +++
(428C)Deﬁnite Severe 10mgIV Overdose Poor
Robertson ODIMI
andTCP+ ++ + +++ ++ ++
(418C)Probabl eSevere 100mgIMImproved
after a
further70mgCPZ
IVModerate
Graham phenelzi ne
60mgdaily
andone
doseIMI
150mg+++ +++ ++ +++ ++ +37.8 8C) Deﬁnite Modera te50mgIM Good
Tackley TCPand
CMI10mg
twice daily
(concu r-
rently)+++ +++ +++ ++ ++ +++
(42.98C)++ +++ Deﬁnite Severe 50mgIM Died Poor
Brodribb,
1995moclobe-
mide300mg
dailyand
imipramine
200mg
daily0 ++ ++ ++ + ++
(39.68C)+ Probabl eSevere 200mgIMIMIlevel
1518mg/lPoor
Gillman,
1996CMI
100mg
ceased 13
days later
TCP30mg++ +++ +++ + ++ + Deﬁnite Modera te100mgIMNore-
sponse to
cyprohep-tadine16mgGood
Gillman,
1997ODCMI
17days la-
teronTCP
30mg+++ +++ ++ +++ + ++ ++ Deﬁnite Modera te50mgIM Same pa-
tient—2episodesModerate
Gillman,
1997TCP40mg
ODCMI
plasmale-
vel150mg/l++ +++ ++ +++ + +++ Deﬁnite Modera te150mgIM Good
Gillman* sertraline
200mg—
ceased 13
days later
TCP30mg++ ++ +++ ++ ++ Deﬁnite Mild 50mgoral Inhospi-
tal—earlyinterven-tionGood
(continued)104 JOURNALOFPSYCHOPHARMACOLOGY13(1)Table2(continued)
Autho rSeroto-
mimeticdrugsRapid
onset Shivering TremorHyper-
active/agitated Confus ion Clonus MyoclonusOcular
oscillationsHyper-
reﬂexiaDiaphor-
esisHyper-
pyrexia Diarrhoea AtaxiaSS
diagnosisSymptom
severityDose
ofCPZ Comments Response
Gillm an* sertrali ne
100mg—
ceased 13
daya later
TCP 30mg++ ++ + ++ ++ ++ Deﬁnit e Mild 50mgoral Inhospi-
tal—earlyinterven-tionModera te
Autho rSeroto-
mimeticdrugsRapid
onset Shivering TremorHyper-
active/agitated Confus ion Clonus MyoclonusOcular
oscillationsHyper-
reﬂexiaDiaphor-
esisHyper-
pyrexia Diarrhoea AtaxiaSS
diagnosisSymptom
severityDose
ofCYP Comments Response
Goldbe rg trazadone
andbuspir-
one0 0 0 0 0 ++ 0 0 0 0 NotSS Mild 12mg Only symp-
tomwas
myoclonusModera te
Muly ﬂuoxeti ne
40mgand
lithium300BD+ ++ ++ ++ ++ ++ ++ 0 Deﬁnit e Mild 12mg
(time un-
stated)LIceased;
improvedover 4daysPoor
Beasley ﬂuoxeti ne
20mg
ceased; 7
days later
TCP 40mg++ ++ ++ ++ Possible Mild 16mg Few details
givenModera te
Lappin isocarb oxa-
zidceased;
11days
later sertra-
line100mg61
only+++ ++ ++ ++ 0 Deﬁnit e Moderate Two doses
of4mg(in
1hr)Proprano-
lol1mg
(IV)gave
norespon seModera te
Klysner isocarb oxa-
zid30mg
daily; ven-
lafaxine75mg
added++ ++ +++ ++ ++ ++ Deﬁnit e Moderate 4mg
6hourly
for‘days’Symptoms
reducedover 6daysPoor
George ﬂuoxeti ne
20mgand
trazod one
100mg0 ++ ++ ++ 0 ++ ++ ++ Probable Moderate 4mgonce
onlyResponded
within30minGood
Gillm an,
1996CMI and
TCP+++ +++ ++ +++ + ++ ++ Deﬁnit e Moderate 16mg Subse-
quently re-
sponded to
CPZNone
CMI,clomipra mine; CPZ, chlorpro mazin e;CYP,cyproheptad ine;IMI, imipram ine;SS,seroton insyndrome; TCP, tranylcy prom ine.0,notpresent ;+,mild; ++,moderate ;+++, severe .
Blankspaceindica tesafeatu rewasnotmentione dorcannotbeinferredfromtherepor t.P.K.GILLMAN:THESEROTONINSYNDROME 105
Features differentiating between SSandNMS (Rosebush
andStewart, 1989; Rosenberg andGreen, 1989; Caroff and
Mann, 1993; Persing, 1994) maybe:NMS, slow onset (days to
weeks) andslow progression over 24–72 hinassociation with
neuroleptics versus SS,both rapid onset andrapid progression
(minutes tohours) inassociation with acombination of
serotonergic drugs; NMS, bradykinesia andleadpipe rigidity
versus SS,hyperkinesia andclonus; andNMS, anidiosyncratic
reaction totherapeutic dosages versus SS,amanifestation of
toxicity (usually toacombination ofdrugs) towhich everyone
isliable.
Insummary, theprecipitating drug deﬁnes thesyndrome:
dopamine (DA) receptor blockers produce bradykinesia
whereas serotonergic drugs produce hyperkinesia.
Treatment
Many treatments forSShave been described including the5-
HT2blockers, methysergide (Sandyk, 1986) andcyprohepta-
dine (seeTable 2)(Goldberg andHuk, 1992; Beasley etal.,
1993; Muly etal.,1993; Lappin and Auchincloss, 1994;
Klysner etal.,1995; George andGodleski, 1996), andthe5-
HT1Ablocker propranolol (Rivers andHorner, 1970; Guze
and Baxter, 1986; Klee and Kronig, 1993; Lappin and
Auchincloss, 1994; Ruiz, 1994; Heisler etal.,1996; Gillman,
1997b). Various benzodiazepines have been used (Halman and
Goldblum, 1990; Ooi, 1991; Lejoyeux etal.,1992; Nierenberg
andSemprebon, 1993; Brannan etal.,1994; Graber etal.,
1994; Ruiz, 1994; Skop etal.,1994; Baetz andMalcolm, 1995;
Reeves andBullen, 1995; Hodgman etal.,1997) aswell as
nitroglycerine (Brown andSkop, 1996), andchlormethiazole
(Bedford-Russel etal.,1992). Neuroleptics have been used,
mostly chlorpromazine asreviewed herein (seeTable 2),but
also chlorprothixene (Morch, 1962) andhaloperidol, unsuc-
cessfully (Bedford-Russel etal.,1992).
Therelative potency forblockade of5-HT2Areceptors by
various drugs isgiven inTable 3(Wander etal.,1987;
Richelson, 1996; Richelson etal.,1997). Chlorprothixene and
sertindole arethemost potent blockers closely followed by
risperidone. Chlorpromazine and cyproheptadine are of
similar, butlesser, potency andhaloperidol hasalowafﬁnity.
Allthese drugs show afﬁnities at5-HT1Areceptors twotothree
orders ofmagnitude less(Wander etal.,1987). This author’s
initial useofchlorpromazine forSS(Gillman, 1997b) was
prompted following thefailure of16mgofcyproheptadine
(orally), which wasthebiggest dose then reported (Goldberg
andHuk, 1992; Beasley etal.,1993; Lappin andAuchincloss,
1994). Thereceptor afﬁnity data (seeTable 3)accords well
with thelimited clinical experience inthese reports, i.e.the
successful useofchlorpromazine, chlorprothixene andcypro-
heptadine andtheapparent failure ofhaloperidol (Bedford-
Russel etal.,1992).
There seems tobeconcern that chlorpromazine would
aggravate seizures bylowering theseizure threshold. Little has
been cited tosupport thisandnone ofthework reviewed here
contains evidence forthis. Espelin used chlorpromazine to
treat hyperpyrexia following amphetamine intoxication, which
presents asimilar picture, andspeciﬁcally stated thatithelped
tonormalize theelectroencephalogram (Espelin andDone,1968). Green alsonoted there wasconcern thatneuroleptics
caused NMS andcould aggravate hyperthermia bylowering
DA(Green etal.,1995). However, thehyperthermia ofNMS is
anidiosyncratic response toneuroleptics; thenormal response
ishypothermia. Indeed there isevidence that normal DA
activity isneeded fortheexpression ofSS(Green and
Grahame-Smith, 1974), thus lowering DA may help to
ameliorate it(Marley andWozniak, 1985). Chlorpromazine
might cause problems bylowering theblood pressure and
would beexpected toworsen theclinical state ifNMS is
confused with SS;itshould alsobenoted thatbromocriptine,
which hasfrequently been used totreat NMS, hasbeen
reported toincrease brain 5-HT levels (Snider etal.,1975) with
theattendant riskthatthiscould worsen SS(Gillman, 1997a)
when itisconfused withNMS. Anexample ofsuch acasemay
bethatofKline etal.(1989) where treatment with dantrolene
andbromocryptine wasgiven toapatient with SSandthe
temperature then rosefrom 38.18Cto42.28Cwithin 3hand
death ensued.
When considering whether drug treatment isrequired it
should benoted theearliest studies indicated thatinanimal
models barbiturate anaesthesia andparalysis reduced body
temperature (Himwich, 1962). Anexample ofthesuccessful
useofanaesthesia, paralysis andactive cooling isthereport of
Peebles-Brown (Peebles-Brown, 1985). Arecent review of
rapid cooling techniques isthatofHarker andGibson (1995).
However, hyperactivity isnotthemain cause ofhyperthermia
(Green etal.,1995) sothese measures alone may notbe
sufﬁcient.
Analysis ofthecases inthisreview suggests areasonable
starting dose fortreatment with chlorpromazine would be
50mgbyIMinjection. Larger doses were used insome cases
(150mgbyIM injection over 2h).InBrodribb’s case
(Brodribb etal.,1994), 100mgbyIMinjection wasgiven
twice in6hwith afurther ﬁvedoses of100mgevery 6h
(orally) until discharge (Brodribb, personal communication).
Insevere cases itisprobably reasonable touseaninitial dosage
of50–100 mgbyIMinjection. Cyproheptadine isonly
available intablet form. Itcanbecrushed andgiven viaa
naso-gastric tube. Doses of4–16 mg,used inreported cases,
maybetoolowforoptimum beneﬁt; Kapur’s recent datausingTable 3Blockade of5-HT2Areceptors by
variou sdrugs
Drug 5-HT2Aafﬁnity
Cyprohep tadine 100
Chlorp romazine 71
Chlorp rothixene 233
Haloperi dol 2.8
Clozap ine 62
Risperi done 170
Olanza pine 25
Sertindo le 260
Methyse rgide 14
Ketans erin 178
Afﬁnity=107761/Kd,whereKd=equilibrium
dissociationinmolarity.
AdaptedfromWanderetal.(1987),Richelson
(1996),Richelsonetal.(1997).106 JOURNALOFPSYCHOPHARMACOLOGY13(1)
positron emission tomography indicate that about 30mgis
needed (asasingle oraldose) toachieve 85–95% blockade of
brain 5-HT2Areceptors (Kapur etal.,1997). This issupported
byoneofthisauthor’s cases where 16mgofcyproheptadine
failed toprovide any amelioration ofsymptoms ina
moderately severe case, whereas chlorpromazine 50mgIM
was followed byresolution ofsymptoms in2h(Gillman,
1997b). Theevidence fortheclinical effectiveness ofchlorpro-
mazine andcyproheptadine inhuman cases ofSSissomewhat
unsatisfactory because itisbased onposthocanalysis ofcase
reports. However, itissupported byextensive data from
animal work that clariﬁes theroleof5-HT. More work is
needed, especially toelucidate theextent towhich various
combinations ofdrugs raise intra-synaptic 5-HT, which is
probably themost important factor determining severity.
Rapid deterioration over 2–4hiswelldocumented inmany
recent reports (Beasley etal.,1993; Brodribb etal.,1994;
Graber etal.,1994; Corkeron, 1995; Brubacher etal.,1996;
George andGodleski, 1996; Gillman, 1996; Mathew etal.,
1996) which suggests aconservative approach totreatment
may notalways bejustiﬁed, especially when potent andlong
acting drugs areimplicated, e.g.non-speciﬁc MAOIs (TCP and
phenelzine) with serotonin reuptake inhibitors likeCMI and
ﬂuoxetine. Even RIMAs likeMOC (inoverdose) have been
involved incases exhibiting rapid deterioration ordeath
(Brodribb etal.,1994; Hernandez etal.,1995; Kuisma, 1995;
Power etal.,1995; Francois etal.,1997).
Conclusions
SSisapotentially serious condition thatcanworsen rapidly.
Paralysis andactive cooling maynotbesufﬁcient treatment in
severe cases; these may require 5-HT2blocking drugs asalife
saving measure. The evidence suggests that cyproheptadine
andchlorpromazine may beeffective. Inmilder cases, these
drugs can provide relief ofdistressing symptoms.
Consideration ofthefactors discussed inthisreview may aid
inbalancing therisks andbeneﬁts ofactive intervention with
drugs. Where thediagnosis isuncertain, and NMS isa
possibility, itmay beadvisable toavoid both bromocriptine
and chlorpromazine. Insuch cases, paralysis and rapid
cooling, and/or cyproheptadine, mayprevent thedevelopment
ofdisseminated intravascular coagulation andother complica-
tions, which canbefatal.
Note:Since theﬁnal draft wasaccepted (January 1998) and
publication (March 1999) there have been sixfurther papers
reporting theuseofcyproheptadine forSSdescribing atotal of
18further cases. These reports donotalter theviews or
conclusions expressed inthepresent paper. [SeealsoGillman
PK(1998) Serotonin syndrome: history andrisk. Fund Clin
Pharmacol 12:482–491.]
Acknowledgements
TheauthorwishestoacknowledgethehelpofMoniqueCichocki
andHelenTrenneryoftheQueenslandDrugInforma tionCentre
andMrs Susan CurlewisofHerstonMedicalLibrary ,Royal
Brisbane Hospital.Addressforcorrespondence
PeterKennethGillman
POBox8183
MountPleasan t
Queensl and4740
Australi a
Email:gillman.k.i@ m130.aone.net.au
References
AmesD,Wirshing WC(1993)Ecstasy,theserotoninsyndrom e,and
neurolepticmalignantsyndrom eapossi blelink?JAMA269:
869^870
AnanthJ,LuchinsA(1977)Areviewofcombinedtricyclicand
MAOItherapy.CompPsychiatry18:221^230
ArnettCD,FowlerJS,MacGregorRR,SchlyerDJ,WolfAP,Lang-
stromB,HalldinC(1987)Turnoverofbrain monoamineoxidase
measuredinvivobypositronemissi ontomograp hyusing L-(11C)
deprenyl.JNeurochem49:522^527
AydFJ(1961a)Acritiqueofantidepressants.DisNervSyst22:32^36
AydFJ(1961b)Toxicsoma ticandpsychopathologicreactionsto
antidepressantdrugs.JNeuropsychiatr2:119^122
BabiakJ(1961)Acase fatalityofoverdoseofacombinationof
tranylcypromin e(parnate)andimipramin e(tofranil ).CanMed
Assoc J85:377^378
BaetzM,MalcolmD(1995)Serotoninsyndromefrom£uvoxamin e
andbuspirone.CanJPsychiatry40:428^429
Beas leyCM,MasicaDN,Heiligenstei nJH,WheadonDE,Zerbe
RL(1993)Possiblemonoamin eoxidase inhibitor^serotonin
uptakeinhibitorinteraction:£uoxetineclinicaldataandprecli-
nical¢ndings .JClinPsychopharmacol13:312^320
BeaumontG(1973)Druginteractionwithclomip ramin e(anafranil ).
JInternMedRes1:480^484
Bedford-RusselAR,SchwartzRH,Dawling S(1992)Accidental
ingestionof`ecstasy'(3,4-methylenedioxyme thamph etamin e).
ArchDisChild67:1114^1115
BenazziF(1996)Serotoninsyndrom ewithmoclobemid e-£uoxetine
combination.Pharma copsychiatry29:162
BodnerRA,LynchT,Lewis L,Kahn D(1995)Serotonin syndrom e.
Neurology45:219^223
Bogdan skiDF,WeissbachH,UndenfriendS(1958)Pharmacological
studieswiththeserotonin precursor5-hydroxytryptophan.J
Pharma colExpTher122:182^194
BowenLW(1964)Fatalhyperpyrexiawithantidepressantdrugs.
BMJ2:14^65
Braitberg G(1994)Serotoninsyndrom e.MedJAust160:527^5 28
Brann anSK,TalleyBJ,BowdenCJ(1994)Sertr alineandisocar -
boxazidcauseaserotoninsyndrome.JClin Psychopharmacol14:
144^145
BrennanD,MacManusM,HoweJ,McLo ughlin J(1988)Neuro-
lepticmalignantsyndrom ewithoutneuroleptics.BrJPsychiatry
152:578^579
BrodribbTR,DowneyM,GilbarPJ(1994)E¤cacyandadverse
e¡ectsofmoclobemid e.Lanc et343:475
BrownTM,SkopBP(1996)Nitroglycerineinthetreatmentofthe
serotoninsyndrome.AnnPharmacother30:191
BrownTM,SkopBP,MarethTR(1996)Pathophysiologyand
managementoftheserotonin syndrom e.AnnPharmacother30:
527^5 33
BrownleeG,Williams GW(1961)Potentiationofamphetamin eand
pethidin ebymonoamin eoxidase inhibitors.Lancet1:669
BrubacherJR(1997)Treatingtheserotoninsyndrom e:antidoteor
support.JToxicolClinToxicol35:213^214P.K.GILLMAN:THESEROTONINSYNDROME 107
BrubacherJR,Ho¡manRS,LurinMJ(1996)Serotoninsyndrome
from venlafaxin e^tranylcypromin einteraction.VetHuman
Toxicol38:358^361
CarlssonA,Lindq vist M(1969)Central andperip heralmono-
amine rgicmembrane-pump blockadebysomeaddictive
analg esicsandantihistamines .JPharm PharmacolChemother
21:460^464
CarlssonA,JonasonJ,LindqvistM(1969)Demonstrationofextra
neuronal5-hydroxytryptamineaccumulationinbrain following
membrane-pumpblockadebychlorimipramin e.BrainRes12:
456^460
Caro¡ SN,MannSC(1993)Neurolepticmalignan tsyndrome.
ContempClinNeurol77:185^202
CiocattoE,FagianoG,BavaGL(1972)Clinicalfeaturesand
treatmentofoverdosageofmonoamin eoxidase inhibitorsand
theirinteractionwithotherpsychotropicdrugs.Resuscitation
1:69^72
ClarkWG,LiptonJM(1986)Changesinbodytemp eratureafter
administr ationofadrenergicandserotonergicagentsand
relateddrugsincluding antidepressan ts:II.Neurosc iBiobehav
Rev10:153^220
ClementAJ,BenazonD(1962)Reactionstootherdrugsinpatients
taking monoamineoxidase inhibitors.Lanc et2:197^198
CocksDP,Passmo re-RoweAH(1962)Dangersofmonoamine
oxidase inhibitors.BMJ2:1545^1546
CoplanD,GormanJM(1993)Detectablelevelsof£uoxetinemetabo-
litesafterdisco ntinuation:anunexpecte dserotoninsyndrom e.
AmJPsychiatry150:837
CorkeronMA(1995)Serotonin syndrom eapoten tiallyfatal
complicationofantidepressan ttherapy.MedJAust163:481^482
Curzon G,EttlingerG,ColeM,Walsh J(1963)Thebiochemical,
behavioralandneurologice¡ectsofhighL-tryptophanintakein
therhesusmonkey.Neurology12:431^438
DentonPH,BorrelliVM,EdwardsNV(1962)Dangersofmonoa-
mineoxidase inhibitors.BMJ2:1752^1753
EspelinDE,DoneAK(1968)Amphetamin epoiso ning.NEnglJ
Med278:1361^1365
FahimJ,Isma ilM,OsmanOH(1972)Theroleof5-hydroxytrypta-
mineandnoradrenalineinthehyperthermicreactioninduced
bypethidin einrabbitspretreatedwithpargyline.BrJPharma col
46:414^416
FelnerAE,WaldmeierPC(1979)Cumu lativee¡ectsofirreversible
MAOinhibitorsinvivo.BiochemPharma col28:995^1002
FjallandB(1979)Neurolepticin£uenceonhyperthermiainducedby
5-hydroxytryptophanandp-methoxyamphetamin einMAOI
pretreatedrabbits.Psychopharmacology63:113^117
FrancoisB,MarquetP,DesachyA,Roustan J,LachatreG,Gastinne
H(1997)Serotoninsyndromeduetoanoverdoseofmoclobemi de
and clomipr amine:apotentiallylifethreatenin gassoc iation.
Intens CareMed23:122^124
GanderDR(1965)Treatmentofdepressiveillness withcombined
antidepressants.Lancet1:107^109
GeorgeTP,Godl eskiLS(1996)Possibleserotonin syndromewith
trazod oneadditionto£uoxetine.BiolPsychiatry39:384^385
GillmanPK(1995)Possibleserotoninsyndrom ewithmoclobemi de
andpethidine .MedJAust162:554
GillmanPK(1996)Successful treatmentofserotonin syndrome
withchlorprom azine.MedJAust165:345
GillmanPK(1997a)Ecstasy,serotoninsyndrom eandthetreatment
ofhyperpyrexia.MedJAust167:109^111
GillmanPK(1997b)Serotonin syndrom etreatedwith chlorprom a-
zine.JClinPsychopharmacol17:128^129
Goldberg RJ,HukM(1992)Serotonin syndromefrom traza done
andbuspirone.Psychosoma tics33:235^236
Goldberg RS,ThorntonWE(1986)Combinedtricyclic^MAOI
therapyforrefractorydepressi on:areviewwithguidelinesfor
appropriateusage.JClinPharmacol18:143^147GraberMA,HoehnsTB,PerryPJ(1994)Sertr aline^phenelzine
druginteraction:aserotoninsyndrom ereaction.AnnPharmaco-
ther28:732^735
GreenAR,Grahame-SmithDG(1974)Theroleofbraindopamine
inthehyperactivitysyndrom eproducedbyincreased5-hydroxy-
tryptamine synthesisinrats.Neuropharmacology13:949^959
GreenAR,Grahame-SmithDG(1976)E¡ects ofdrugsonthe
processes regul ating thefunctional activityofbrain5-hydroxy-
tryptamine .Nature260:487^491
GreenAR,CrossAJ,Good winGM(1995)Reviewofthepharma-
cology and clinicalpharmacology of3,4-methylenedioxy-
methamphetamine(MDMA or`ecstasy').Psychopharmacology
119:247^260
GuzeBH,Baxte rLR(1986)Theserotoninsyndrome:case respon-
sivetopropranolol.JClinPsychopharmacol6:119^120
Halma nM,GoldblumBS(1990)Fluoxetineandneurolepticmalig-
nantsyndrom e.BiolPsychiatry28:518^521
HansenTE,DieterK,Keeper sGA(1990)Interactionof£uoxetine
andpentazocine.AmJPsychiatry147:949^950
HarkerJ,GibsonP(1995)Heat-stroke:areviewofrapidcooling
techniques.IntensCritCareNursing11:198^202
HarrerG(1961)ZurInkompatibilitatzwischenMonoaminooxydase-
hemmernundImipramin. WienMedWschr111:5^51
HeislerMA,GuidryJR,ArneckeB(1996)Serotonin syndrom e
inducedbytheadministr ationofvenlafaxin eandphenelzine.
AnnPharma cother30:84
HernandezAF,MonteroMN,PlaA,VillanuevaE(1995)Fatal
moclobemideoverdoseordeathcausedbyserotoninsyndrom e?
JForensicSci40:128^130
HessSM,DoepfnerW(1961)Behavioural e¡ectsandbrain amine
contentinrats.ArchIntPharma codynTher134:89^99
HessSM,Red¢eldBG,UnderfriendS(1959)Thee¡ectofmonoa-
mineoxidase inhibitors andtryptophanonthetryptamine
contentofanimaltissuesandurine.JPharmacolExpTher127:
178
HiltonSE,Maradi tH,MollerHJ(1997)Serotonin syndromeand
drugcombinations:focus onMAOIand RIMA. EurArch
PsychiatryClinNeurosci247:113^119
HimwichWA(1962)Interactionofmonoamineoxidase inhibitors
with imipramin eandsimilar drugs.RecentAdvBiolPsychiatry
4:257
HimwichWA,Peterse nJC(1961)E¡ectofthecombinedadminis-
trationofimipramin eandamonoamin eoxidase inhibitor.AmJ
Psychiatry117:928^929
Hodgman MJ,Martin TG,KrenzelokEP(1997)Serotonin
syndrom eduetovenlafaxin eandmain tenancetranylcypromine
therapy.Human ExpToxicol16:14^17
Horita A,GogertyJH(1958)Thepyretogenice¡ectof5-hydroxy-
tryptophananditscompar isonwithLSD.JPharma colExpTher
122:195^200
HowarthE(1961)Possiblesynergisti ce¡ects ofthenewthymol-
epticsinconnectionwithpoiso ning.JMentSci107:100^103
InselT,RoyB,CohenR,MurphyD(1982)Possibledevelopmentof
theserotoninsyndrom einman. AmJPsychiatry139:954^955
JahrJS,Pisto JD,GitlinMC,O'NeillPT(1994)Theserotonin
syndrom einapatientreceiving sertr aline afteranankleblock.
Anesth Analg79:189^191
JounelaAJ,MattilaMJ,KnollJ(1977)Interactionofselectiveinhi-
bitors ofmonoamin eoxidase with pethidine intherabbit.
BiochemPharma col26:806^808
KapurS,Zipurs kyRB,JonesC,WilsonAA,DasilvaJD,HouleS
(1997)Cyproheptadine: apotentinvivoserotoninantagonist.
AmJPsychiatry154:884
KeltnerN(1994)Serotoninsyndrom e:acaseoffatalSSRI /MAOI
interaction.PerspectPsychiatrCare30:26^31
KleeB,KronigMH(1993)Casereport ofprobablesertra line
inducedakathisia .AmJPsychiatry150:986^987108 JOURNALOFPSYCHOPHARMACOLOGY13(1)
KlineSS,MauroLS,Scala-BarnettDM,ZickD(1989)Serotonin
syndrom eversusneurolepticmalignan tsyndrome asacauseof
death.ClinPharm 8:510^514
KlysnerR,LarsenJK,SerensenP,HyllestedM,Pedersen-DyrlundB
(1995)Toxicinteractionofvenlafa xineandisocarboxazid.Lancet
346:1298^1299
KuismaMJ(1995)Fatalserotonin syndrome with trismus.Ann
EmergMed26:108
Lane R,BaldwinD(1997)Selectiveserotoninreuptakeinhibitor-
inducedserotonin syndrom e:review.JClinPsychopharmacol17:
208^221
LappinRI,AuchinclossEL(1994)Treatmentoftheserotonin
syndrom ewithcypro heptadi ne.NEnglJMed331:1021^1022
LejoyeuxM,FineyreF,AdesJ(1992)Theserotoninsyndrom e.AmJ
Psychiatry149:1410^1411
LejoyeuxM,RouillonF,Le¨onE,Ade©sJ(1995)Theserotonin
syndrom e:reviewoftheliterature anddescriptionofanoriginal
study.Encephale22:537^543
Liebenberg R,BerkM(1996)Serotonergicsyndrom eafterconcomi-
tantuseofmoclobemid eand£uoxetine.HumPsychopharma col
11:146^147
Lieberman J,KaneJM,ReifeR(1985)Neuromusculare¡ectsof
monoamin eoxidaseinhibitors.JClinPsychopharma col5:221^228
Lond onDR,MilneMD(1962)Dangersofmonoamineoxidase inhi-
bitors.BMJ2:17^52
LovelessAH,MaxwellDR(1965)Acompar isonofthee¡ects of
imipraminetrimipramine and someotherdrugs inrabbits
treatedwithamonoamin eoxidase inhibitor.BrJPharma col25:
158^170
MarleyE,WozniakKM(1983)Clinicalandexperi mentalaspec tsof
interactionsbetweenamineoxidase inhibitors and aminere-
uptakeinhibitors.PsycholMed13:735^749
MarleyE,WozniakKM(1984a)Interactionsofanon-selective
monoamin eoxidase inhibitor,phenelzine,withinhibitorsof5-
hydroxytryptamine,dopamine ornoradrenalinere-uptake.J
PsychiatrRes18:173^189
MarleyE,Wozniak KM(1984b)Interactionsofnon-selectivemono-
amineoxidase inhibitors,tranylcypromin eandnialamide,with
inhibitorsof5-hydroxytryptamine ,dopamine andnoradrenaline
re-upta ke.JPsychiatrRes18:191^203
MarleyE,Wozniak KM(1985)Interactionsbetw een relatively
selectivemonoamineoxidase inhibitorsandaninhibitorof5-
hydroxytryptaminere-uptak e,clomipr amine .JPsychiatrRes19:
597^608
MarsdenCA,Curzon G(1979) The roleoftryptamine inthe
behavioural e¡ectsoftranylcypromin e+L-tryptophan.Neuro-
pharm acology18:159^164
MartinTG(1996)Serotonin syndrom e.AnnEmergMed28:520^526
Mason BJ,Blackburn KH(1997)Possibleserotonin syndrom easso-
ciatedwithtramad oland sertra linecoadministr ation.Ann
Pharma cother31:175^177
MathewNT,TietjenGE,LuckerC(1996)Serotoninsyndrom e
complicatingmigrainepharmacotherapy.Cephalalgia16:323^327
MillsKC(1995)Serotonin syndrome.AmFamPhysician52:1475^
1482
MitchellRS(1955)Fataltoxicencephalitisoccurring duringipro-
niazidtherapyinpulmo narytuberculosis.AnnInternMed42:
417^424
MollerNielsenI(1980)Tricyclicantid epressan ts:generalpharma-
cology.InHofmeister F,StilleG(eds),Psychotropicagentspart1:
antipsychoticsandantidepressan ts.Springer-Verlag,Berlin
MorchR(1962)Noglemedicamenteltfremkaldtedelirosetilstand e.
UgeskrLaeger124:614^615
MulyEC,McDo nald W,Ste¡ensD,BookS(1993)Serotonin
syndrom eproducedbyacombinationof£uoxetineandlithium.
AmJPsychiatry150:15^65NeuvonenPJ,Pohjola-SintonenS,TackeU,VuoriE(1993)Fivefatal
casesofserotoninsyndrom eaftermoclobemid e-citalopramor
moclobemide-clomipramin eoverdoses.Lancet342:14^19
Nierenberg DW,SemprebonM(1993)Thecentralnervoussystem
serotoninsyndrome.Clin Phama colTher53:84^88
NimmoSM,KennedyBW,TullettWM,BlythAS,DougallJR
(1993)Drug-inducedhyperthermia.Anaesthesia48:892^895
NymarkM,MollerNeilsenI(1963)Reactionsduetothecombina-
tionofmonoamineoxidase inhibitors withthymoleptics,
pethidin eormethylamph etamin e.Lanc et2:524^525
OatesJA,SjoerdsmaA(1960)Neurologice¡ectsoftryptophan in
patientsreceiving amonoamineoxidase inhibitor.Neurology10:
1076^1078
OefeleKV,GrohmannR,RutherE(1986)Adversedrugreactionsin
combinedtricyclicandMAOItherapy.Pharma copsychiatry19:
243^244
OoiTK(1991)Theserotoninsyndrom e.Anaesthesia46:507^508
Palmer H(1960)Potentiationofpethidin e.BMJ2:944
PappC,BenaimS(1958)Toxice¡ectsofiproniazidinapatientwith
angina. BMJ2:1070^1 072
PatoNT,MurphyDL,DeVaneCL(1991)Sustaine dplasmaconcen-
trationsof£uoxetineand/ornor£uoxetinefourandeightweeks
after£uoxetine disco ntinuation.JClinPsychopharmacol11:
224^225
Peebles-BrownAE(1985)Hyperpyrexiafollowing psychotropic
drugoverdose.Anaesthesia40:1097^1099
PennRG,RodgersKJ(1971)Compar isonofthee¡ectsofmorphin e,
pethidin eandpentazocineinrabbitspretreatedwithamono-
amineoxidase inhibitor.BrJPharmacol42:485^492
PersingJS(1994)Neurolepticmalignantsyndrome:anoverview.
SDakotaJMedicine47:51^55
PollockRA,WatsonRL(1971)Malignan thyperthermiaassoc iated
with hypocal caemia.Anesth esiology34:188
PowerBM,PinderM,HackettLP,IlettKF(1995)Fatalserotonin
syndromefollowing acombinedoverdoseofmoclobemide,clomi-
pramin eand£uoxetine.Anaesth IntensCare23:499^502
Raza niJ,WhiteKL,White J,Simpso nG,Sloane RB,RebalR,
PalmerR(1983)Thesafetyande¤cacyofcombinedamitripty line
andtranylcypromin eantidepressan ttreatment.Acontrolled
trial.ArchGenPsychiatry40:657^661
ReevesR,BullenJ(1995)Serotonin syndromeproducedbyparoxe-
tineandlow-dosetrazod one.Psychosoma tics36:159^160
ReidNCRW(1962)Pethidine andphenelzine.BMJ1:408
Richelson E(1984)Antagonismbyantidepressan tsofneurotrans -
mitte rreceptorsofnormal human brain invitro.JPharmacol
ExpTher23:94^102
Richelson E(1996)Preclinicalpharma cologyofneuroleptics:focus
onnewgenerationcompounds.JClin Psychiatry11:4^11
RichelsonE,SouderT,Acuna J,ChouT(1997)Bindi ngstudieswith
somenewneurolepticsathumanbrainreceptors.BiolPsychiatry
41:67S
RiversN,HornerB(1970) Possiblelethalinteractionbetw een
Nardilanddextrom ethorphan. CanMedAssoc J103:85
RobertP,SenardJM,FabreM,CabotC,CathalaB(1996)Syndrom e
se¨rotoninergiquelorsd'uneintoxicationaigueauxantide¨pres-
seurs.AnnFrAnesthRe¨anim15:663^665
RogersKJ,ThorntonJA(1969)Theinteractionbetw eenmonoa-
mineoxidase inhibitorsandnarcoticanalgesicsinmice.BrJ
Pharma col36:470^480
Rose bushP,StewartT(1989)Aprospecti veanalysisof24episodes
ofneurolepticsyndrom e.AmJPsychiatry149:717^725
Rose nberg MR,GreenM(1989)Neurolepticmalignan tsyndrom e:a
reviewofresponse totherapy.AnnIntern Med149:192^731
RuizF(1994)Fluoxetineandtheserotoninsyndrom e.AnnEmerg
Med24:983^985
Sand ykR(1986)L-Dopainducedserotoninsyndrom einaParkinso-
nian patientonbrom ocriptine.JClinPsychopharm acol6:194^195P.K.GILLMAN:THESEROTONINSYNDROME 109
SchuckitM,RobinsE,FeighnerJ(1971)Tricyclicantidepressan ts
and monoamin eoxidase inhibitors.ArchGen Psychiatry24:
509^514
SethnaER(1974)Astudyofrefractorycasesofdepressiveillness
andtheirresponsetocombinedantidepressan ttreatment.BrJ
Psychiatry124:265^272
SheeJC(1960)Dangerouspotentiationofpethidin ebyiproniazid
anditstreatment.BMJ2:507^509
SinclairJG(1973)Dextromethorphan ^monoamin eoxidase inhi-
bitorinteractioninrabbits.JPharmPharmacol25:803^808
SkopBP,Finkelstein JA,MarethTR,MagoonMR,BrownTM
(1994)Theserotoninsyndrom eassoci atedwithparoxetine,an
over-the-countercoldremedy,andvascul ardisease .AmJEmer-
gencyMed12:642^644
SniderSR,HuttCS,SteinB,FahnS(1975)Increase inbrainsero-
toninproducedbybrom ocriptine.NeurosciLett1:237^24 1
Sovner R,WolfeJ(1988)Interactionbetweendextromethorphan
andmonoamineoxidase inhibitortherapywithisocar boxazid.N
EnglJMed319:16^71
SporerKA(1995)Theserotoninsyndrome implicateddrugs,patho-
physiologyandmanagement.DrugSafety13:94^104
Staufenberg EF,TantumD(1989)Malignan thyperthermia
syndrom eincombinedtreatment.BrJPsychiatry154:577^578SternTA,SchwartzJH,SchusterJL(1992)Catastro phicillness
associ atedwiththecombinationofclomipr amine ,phenelzine,
andchlorprom azine.AnnClin Psychiatry4:81^85
SternbachH(1991)Theserotoninsyndrom e.AmJPsychiatry148:
705^713
TackleyRM,TregaskisB(1987)Fataldissemina tedintravascular
coagulationfollowing amonoamin eoxidase inhibitor/tricyclic
interaction.Anaesthesia42:760^763
TaylorDC(1962)Alarming reactiontopethidin einpatientson
phenelzine.Lancet2:401^402
Vigran IM(1964)Dangerouspoten tiationofmeperidinehydro-
chloridebypargylinehydrochloride.JAMA187:953^954
WanderTJ,NelsonA,Okazaki H,RichelsonE(1987)Antagonism by
neurolepticsofserotonin 5-HT 1Aand5-HT 2receptors of
normalhuman brain invitro.EurJPharma col143:279^282
White K,Simpso nG(1981)CombinedMAOI^tricyclicantidepres-
santtreatment:areevaluation.JClinPharmacol1:264^281
ZornbergGL(1993)Adverseinteractionbetw eenpropoxyph ene
andphenelzine.AmJPsychiatry150:1269^1270
ZornbergGL,Bodkin JA,CohenBM(1991)Severeadverseinterac-
tionbetweenpethidin eandselegiline .Lanc et337:246